

EMA/850458/2017

European Medicines Agency decision

P/0021/2018

of 30 January 2018

on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMEA-001797-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0021/2018

of 30 January 2018

on the acceptance of a modification of an agreed paediatric investigation plan for human normal immunoglobulin (EMA-001797-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0084/2016 issued on 18 March 2016,

Having regard to the application submitted by Octapharma Pharmazeutika Produktionsges.m.b.H on 22 September 2017 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 December 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for human normal immunoglobulin, solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Octapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Straße 235, 1100 – Vienna, Austria.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/635219/2017

London, 15 December 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001797-PIP01-15-M01

Scope of the application

Active substance(s):

Human normal immunoglobulin

Condition(s):

Treatment of primary immunodeficiency

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Octapharma Pharmazeutika Produktionsges.m.b.H

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Octapharma Pharmazeutika Produktionsges.m.b.H submitted to the European Medicines Agency on 22 September 2017 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0084/2016 issued on 18 March 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 17 October 2017.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.



Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of primary immunodeficiency

The waiver applies to:

- all subsets of the paediatric population from birth to less than 2 years of age;
- for solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Treatment of primary immunodeficiency

2.1.1. Indication(s) targeted by the PIP

Treatment of primary immunodeficiency syndromes as a model for replacement therapy in:

- replacement therapy in primary immunodeficiency syndromes with impaired antibody production;
- replacement therapy in hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibodies have failed;
- replacement therapy in hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients (MM) who have failed to respond to pneumococcal immunisation.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Development of a 12 ml vial appropriate for the paediatric population from 2 to less than 6 years of age
Non-clinical studies	0	Not applicable

Clinical studies	1	Open-label, uncontrolled trial to evaluate pharmacokinetics, safety, efficacy and tolerability of human normal immunoglobulin in children from 2 years to less than 18 years of age with primary immunodeficiency syndromes
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2018
Deferral for one or more measures contained in the paediatric investigation plan:	Yes